Biotech: Core and Explore – Pfizer Inc. (PFE), Merck & Co., Inc. (MRK)

Page 1 of 3

Giant pharmaceutical companies are looking for the next big drug, and so are much smaller biotech outfits. Because of the methods they use, biotechs are often at the leading edge of research. This, combined with the small size of many of the companies in this space, means the potential for investors to hit home runs. However, it also opens up the possibility for a lot of strike outs. Investors interested in the drug space should consider owning biotechs, but would do well to use a core and explore approach.

Pfizer Inc. (NYSE:PFE)

Biotech Versus Pharmaceutical Company

Drugs are an increasingly important aspect of everyday life. With the aging of the Baby Boomers, drug use is only going to increase. The next big drug, however, isn’t going to show up out of thin air. That means that companies big and small are going to be looking for it.

The major pharmaceutical companies spend hundreds of millions of dollars on this endeavor, focusing on manipulating chemicals into useful compounds. Many of these companies are household names, like Dow-30 members Merck & Co., Inc. (NYSE:MRK) and Pfizer Inc. (NYSE:PFE). These companies are massive entities that have large collections of businesses generating revenue to support their research efforts. These are the companies most investors think of when they consider drugs.

There is another avenue to the creation of drugs, however. The Biotechnology Industry Organization explains that biotechnology “harnesses cellular and biomolecular processes to develop technologies and products that help improve our lives and the health of our planet.” In other words, what biotech companies create comes from living organisms.

It is a unique approach and one that many would suggest we haven’t even begun to fully tap. For example, the rainforests of the world are home to many species of animals and plants that we’ve never even seen. The opportunities to find novel drugs via biotechnology is immense.

The Core

There is really only one truly large biotech company out there, Amgen, Inc. (NASDAQ:AMGN). Luckily for investors, Amgen happens to be a well-run and financially sound company. In an industry known for volatility, Amgen is a relative safe haven. It even initiated a dividend in 2012, lending further credence to its status as the 800-pound gorilla of biotech. That said, some investors may believe that the company’s size and new dividend are evidence that Amgen isn’t a growth company anymore.

While it will likely be hard for the company to grow as quickly as it once did, it hasn’t stopped innovating. In fact, it currently has eight drugs in late stage development, including treatments for postmenopausal osteoporosis, gastric and ovarian cancers, acute lymphoblastic leukemia, and psoriasis.  Some of these ailments are likely to be increasingly common as the baby boomers continue to age, making them great candidates to pick up the slack when biosimilars (the equivalent of generic drugs) of Amgen’s existing blockbusters are allowed on the market.

Page 1 of 3
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

5 Retirement Mistakes To Avoid (and Einstein’s Famous Quote)

11 Smartest People in the World

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Warren Buffett and Billionaires Are Crazy About These 7 Stocks

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!